Involvement of Rho-Kinase Pathway in Contractile Activity of Rabbit RPE Cells In Vivo and In Vitro

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 2, 2004, Pages 668-674

  Zheng, Yuping ^a   Bando, Hajime ^a   Ikuno, Yasushi ^a   Oshima, Yusuke ^a   Sawa, Miki ^a   Ohji, Masahito ^a   Tano, Yasuo ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALPHA ACTIN; COLLAGEN TYPE 1; PROTEIN KINASE INHIBITOR; RHO KINASE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RABBIT; RETINA; VITREORETINOPATHY;

ACTINS; AMIDES; ANIMALS; CELL DIVISION; CELLS, CULTURED; COLLAGEN TYPE I; ENZYME INHIBITORS; FEMALE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PIGMENT EPITHELIUM OF EYE; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RABBITS; VITREORETINOPATHY, PROLIFERATIVE;

EID: 0942298142     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0808     Document Type: Article

References (48)

1. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995;79:953-960.
2. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3-18.
3. Walshe R, Esser P, Wiedemann P, et al. Proliferative retinal diseases: myofibroblasts cause chronic vitreoretinal traction. Br J Ophthalmol. 1992;76:550-552.
4. Casaroli-Marano RP, Pagan R, Vilaro S. Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1999;40:2062-2072.
5. Lee SC, Kwon OW, Seong GJ, Kim SH, Ahn JE, Kay ED. Epitheliomesenchymal transdifferentiation of cultured RPE cells. Ophthalmic Res. 2001;33:80-86.
6. Lee SC, Kim SH, Koh HJ, Kwon OW. TGF-betas synthesized by RPE cells have autocrine activity on mesenchymal transformation and cell proliferation. Yonsei Med J. 2001;42:271-277.
7. Grisanti S, Guidry C. Transdifferentiation of retinal pigment epithelial cells from epithelial to mesenchymal phenotype. Invest Ophthalmol Vis Sci. 1995;36:391-405.
8. Kurosaka D, Muraki Y, Inoue M, Katsura H. TGF-beta 2 increases alpha-smooth muscle actin expression in bovine retinal pigment epithelial cells. Curr Eye Res. 1996;15:1144-1147.
9. Stocks SZ, Taylor SM, Shiels IA. Transforming growth factor-beta1 induces alpha-smooth muscle actin expression and fibronectin synthesis in cultured human retinal pigment epithelial cells. Clin Experiment Ophthalmol. 2001;29:33-37.
10. Bochaton-Piallat ML, Kapetanios AD, Donati G, Redard M, Gabbiani G, Pournaras CJ. TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci. 2000;41:2336-2342.
11. Grierson I, Mazure A, Hogg P, et al. Non-vascular vitreoretinopathy: the cells and the cellular basis of contraction. Eye. 1996;10:671-684.
12. Grierson I, Hiscott P, Hogg P, et al. Development, repair and regeneration of the retinal pigment epithelium. Eye. 1994;8:255-262.
13. Glaser BM, Cardin A, Biscoe B. Proliferative vitreoretinopathy: the mechanism of development of vitreoretinal traction. Ophthalmology. 1987;94:327-332.
14. Majno G, Gabbiani G, Hirschel BJ, et al. Contraction of granulation tissue in vitro: similarity to smooth muscle. Science. 1971;173:548-550.
15. Gabbiani G, Hirschel BJ, Ryan GB, et al. Granulation tissue as a contractile organ: a study of structure and function. J Exp Med. 1972;135:719-734.
16. Harris AK, Stopak D, Wild P. Fibroblast traction as a mechanism for collagen morphogenesis. Nature. 1981;290:249-251.
17. Hinz B, Gabbiani G, Chaponnier C. The NH2-terminal peptide of alpha-smooth muscle actin inhibits force generation by the myofibroblast in vitro and in vivo. J Cell Biol. 2002;157:657-663.
18. Takai Y, Sakaki T, Tanaka K, Nakanishi H. Rho as a regulator of the cytoskeleton. Trends Biochem Sci. 1995;20:227-231.
19. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509-514.
20. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res. 2000;261:44-51.
21. Narumiya S, Ishizaki T, Watanabe N. Rho effectors and reorganization of actin cytoskeleton. FEBS Lett. 1997;410:68-72.
22. Ishizaki T, Naito M, Fujisawa K, et al. p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett. 1997;404:118-124.
23. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem. 1995;270:29051-29054.
24. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996;15:2208-2216.
25. Amano M, Chihara K, Kimura K, et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science. 1997;275:1308-1311.
26. Amano M, Mukai H, Ono Y, et al. Identification of a putative target for Rho as the serine-threonine kinase protein kinase N. Science. 1996;271:648-650.
27. Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem. 1996;271:20246-20249.
28. Katoh K, Kano Y, Amano M, Kaibuchi K, Fujiwara K. Stress fiber organization regulated by MLCK and Rho-kinase in cultured human fibroblasts. Am J Physiol. 2001;280:C1669-C1679.
29. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-994.
30. Tada S, Iwamoto H, Nakamuta M, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol. 2001 34:529-536.
31. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and out-flow facility. Invest Ophthalmol Vis Sci. 2001;42:137-144.
32. Matsumoto Y, Tanaka K, Harimaya K, Nakatani F, Matsuda S, Iwamoto Y. Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells. Jpn J Cancer Res. 2001;92:429-438.
33. Kuwahara K, Saito Y, Nakagawa O, et al. The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes: possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett. 1999;452:314-318.
34. Flood MT, Gouras P, Kjeldbye H. Growth characteristics and ultrastructure of human retinal pigment epithelium in vitro. Invest Ophthalmol Vis Sci. 1980;19:1309-1320.
35. Jain PT, Pento JT, Graves DC. Cell-growth quantitation methods for the evaluation of antiestrogens in human breast cancer cells in culture. J Pharmacol Toxicol Methods. 1992;27:203-207.
36. Akira A, Mami U, Masanobu U. Enhancement of dedifferential and myoid differentiation of retinal pigment epithelial cells by platelet derived growth factor. Br J Ophthalmol. 2000;84:1306-1311.
37. Ikuno Y, Kazlauskas A. TGFbeta1-dependent contraction of fibroblasts is mediated by the PDGF alpha receptor. Invest Ophthalmol Vis Sci. 2002;43:41-46.
38. Ikuno Y, Leong FL, Kazlauskas A. PI3K and PLCgamma play a central role in experimental PVR. Invest Ophthalmol Vis Sci. 2002;43:483-489.
39. Fastenberg DM, Diddie KR, Dorey K, Ryan SJ. The role of cellular proliferation in an experimental model of massive periretinal proliferation. Am J Ophthalmol. 1982;93:565-572.
40. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell. 2001;12:2730-2741.
41. Connor TB Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989;83:1661-1666.
42. Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci. 1999;40:705-712.
43. Jerdan JA, Pepose JS, Michels RG, et al. Proliferative vitreoretinopathy membranes: an immunohistochemical study. Ophthalmology. 1989;96:801-810.
44. Murata T, Arii S, Nakamura T, Mori A, et al. Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. J Hepatol. 2001;35:474-481.
45. Ikuno Y, Leong FL, Kazlauskas A. Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor. Invest Ophthalmol Vis Sci. 2000;41:3107-3116.
46. Ito S, Sakamoto T, Tahara Y, et al. The effect of tranilast on experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1999;237:691-696.
47. Ikuno Y, Kazlauskas A. An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. Invest Ophthalmol Vis Sci. 2002;43:2406-2411.
48. Carrington L, McLeod D, Boulton M. IL-10 and antibodies to TGF-beta2 and PDGF inhibit RPE-mediated retinal contraction. Invest Ophthalmol Vis. 2000;41:1210-1216.